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SUMMARY
Introduction Pseudomembranous necrotizing Aspergillus tracheobronchitis is a rare form of pulmonary 
aspergillosis which occurs in immunocompromised patients.
Case Outline A female patient aged 71, suffering from acute myeloid leukemia, developed the symptoms 
of progressive shortness of breath and inspiratory stridor. The diagnosis in our case was made on the 
histological findings from tissues obtained by bronchoscopy. A chest CT scan suggested the state of the 
compromised trachea and left principal bronchus lumen. The long-term regimen with itraconazole in 
the dose of 400 mg/24 hours proved efficient in our patient.
Conclusion Progressive shortness of breath and inspiratory stridor in immunocompromised patients 
along with radiological and CT changes should be also considered as pulmonary aspergillosis in dif-
ferential diagnosis.
Keywords: aspergillosis; acute myeloid leukemia; trachea; large bronchi; immunodeficiency; antifungal 
medicament
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INTRODUCTION
Pseudomembranous necrotizing Aspergillus 
tracheobronchitis (PNTB) is a rare form of in-
vasive pulmonary aspergillosis which occurs 
in immunocompromised patients, primarily 
those with neutropenia, hematological disor-
ders, acquired immunodeficiency syndrome 
(AIDS), and patients who underwent bone 
marrow or organ transplantation. The diagnos-
tic criteria include Aspergillus isolation from 
the cultures of tracheobronchial tree samples, 
or the histological confirmation of Aspergillus 
in the affected tissue, along with confirma-
tion of the absence of alternative diagnosis, as 
well as the absence of radiological, clinical and 
histological evidence of invasive parenchymal 
aspergillosis [1].
Aspergillus tracheobronchitis (ATB) can be 
manifested as obstructive tracheobronchitis, 
ulcerative tracheobronchitis and PNTB, the 
latter being the most unfavorable form of ATB. 
PNTB is known to have a fatal outcome in 90% 
of patients, regardless of the administered anti-
fungal drug [2-5]. The degree of immune dys-
function is crucial for treatment outcome [4].
CASE REPORT
A 71-year-old female patient, non-smoker, was 
admitted at the Institute for Pulmonary Dis-
eases of Vojvodina as an emergency case, with 
dyspnea, orthopnea and inspiratory stridor, 
immediately after completed second chemo-
therapy course (cytosine arabinoside + dau-
noblastin) according to the protocol for acute 
myeloblastic leucemia (AML). There were no 
other illnesses before. Laboratory findings re-
vealed leukocytosis (WBC 13.9×109/L), eryth-
rocyte count of 3.59×1012/L, hemoglobin 113 
g/L, and platelets 301×109/L. Biochemistry 
findings involving glucosa, urea, creatinine, 
sedimentation rate, C-reactive protein (CRP), 
fibrinogen, and coagulation status were within 
the reference values range, except for lactate 
dehydrogenase (LDH) that was 240 U/L. On 
admission the patient showed global respira-
tory failure with tachypnea within 24 min. Ox-
ygen saturation was 94%, oxygen partial pres-
sure of 10:00 kPa and carbon dioxide 6:54 kPa.
The standard chest X-ray finding revealed ex-
tended shadow of the upper mediastinum and 
cardiac vessel shadows, with reduced transpar-
ency at lung bases. The CT scan of the chest 
revealed a stricture in the lumen of the trachea 
and the left main bronchus, as well as a moder-
ate mediastinal lymphadenomegaly. Extended 
cardiac structures and stain-like lesions of the 
lung parenchyma were detected primarily in 
the lower lobes of both lungs (Figure 1). Bron-
choscopic examination showed normal find-
ings of the larynx, but with strictures of the tra-
chea and with hyperemic mucosa which abun-
dantly bled during contact with the instrument. 
The tracheal lumen was covered with necrotic, 
soft yellowish masses. The masses were par-
tially covering tracheal mucosa in the form of 
a pseudo membrane, which reduced the lumen 
of the trachea. This content was also present at      
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the bifurcation and at the orifice of the left main bronchus 
(Figure 2). The bronchial biopsy sample revealed a piece 
of bronchial mucosa, which surface was partially ulcerated 
and partially covered by a yellowish pseudomembrane, of 
which the necrotic lamina propria was composed, and was 
also permeated with fibrinous threads and thick lympho-
cyte infiltrates, plasma cells and neutrophile granulocytes. 
Within pseudomembranes and blood vessel lumens of the 
lamina propria, there were numerous branched hyphae 
of the Aspergillus strain fungus, confirmed by PAS (Peri-
odic acid-Schiff) and GMS (Gomori methenamine silver) 
staining methods. The definite histopathological diagnosis 
was pseudomembranous necrotizing bronchial aspergil-
losis (PNBA) (Figure 3).
Treatment was initiated immediately after admission, 
including a controlled oxygenation using a 24% volume 
mask, crystaloid infusions, bronchodilators, gastropro-
tective drugs, short-term insulin and thyroid hormones 
substitution. Oral itraconazole 2×200 mg/24 hours was 
introduced in the treatment following seven weeks.
In the following seven days, the patient responded to 
the applied treatment with improved dyspnea and inspira-
tory stridor. The maintenance dose (2×100 mg/24 hours) 
proved sufficient to achieve a control of the respiratory 
symptoms induced by PNTB during the 4-month period 
after the diagnosis. Five days after bronchoscopy, CT for 
three-dimensional visualization of the trachea and large 
bronchi (virtual bronchoscopy) was performed, detecting 
a few exophytic, polypoid and sessile lesions with regular, 
arch-shaped contours with the following localizations: 
sublaryngeal on the right, next to the left lateral wall of the 
trachea at the level of the aortic arch, next to the carina of 
the trachea, and in the left main bronchus with deformed 
Figure 1. Thoracic CT scans
Figure 3. Numerous Aspergillus hyphae in necrotic tissue (HE, 200×)
Figure 2. First bronchoscopy shows whitish fungal plaques obstruct-
ing the lower trachea  
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and thickening bronchial all along. The precipitation test 
finding for Aspergillus was negative. The broncoscopy 
performed 21 days after the initial one, showed general 
improvement. The lumen of the trachea was free, without 
pseudomembranes (Figure 4). The left main bronchus was 
deformed in shape of circular stenosis, with vulnerable 
mucosa which was bleeding on contact. The right main 
bronchus was passable. During hospitalization, additional 
virtual bronchoscopy was also performed, confirming sat-
isfactory regression of the registered exophytic endolumi-
nal lesions.
DISCUSSION
Invasive pulmonary aspergillosis makes 90% of all clinical 
forms of pulmonary aspergillosis, and 7-20% of these in-
fections are manifested by a concurrent involvement of the 
tracheobronchial tree [1]. As an isolated form of invasive 
pulmonary aspergillosis, PNBA is found in 7-10% of the 
affected patients [6].
ATB may be manifested in the form of aspergillus bron-
chitis, obstructive tracheobronchitis, ulcerative tracheo-
bronchitis, and PNBA [2-6]. New classification divides 
ATB in immunodeficient patients into three forms [7, 8, 
9]: 1) mucous deposits and plaques with no inflammatory 
response signs in the bronchial mucosa (this form is usually 
found in the patients with heart transplantation and AIDS); 
2) pseudomembranous aspergillosis of the trachebronchial 
tree accompanied by an extensive inflammation with pseu-
domembranous deposits covering the mucosa and contain-
ing Aspergillus; 3) ulcerous aspergillosis of the tracheobron-
chial tree manifested as a local infection in the region of the 
pulmonary transplant suture – this form has a good prog-
nosis and a good response to instillation of antifungal drugs 
during bronchoscopy and to surgical debridement [1].
We report a very rare case of pseudomembranous necro-
tizing aspergillosis of the large airways in the form of the 
local invasive aspergillosis of the trachea and bronchi, 
emphasizing a characteristic appearance of intraluminal, 
superficial and circumferrential pseudomembranes con-
taining fibrin and Aspergillus hyphae that resulted in the 
obstruction of the airways with persisting fever despite 
the applied antibiotics. The diagnosis can be based on the 
identification of the agent in sputum, bronchial lavage 
fluid, broncho-alveolar lavage fluid (BAL), transthoracic 
percutaneous needle aspiration sample or biopsy sample 
[10]. Blood cultures are less useful for diagnosis even in 
disseminated infections. The diagnostic method of choice 
is bronchoscopy with bronchobiopsy, but attention should 
be raised due to the risk of bleeding during the interven-
tion and sampling. Galaktomannan (GM), antigen, resid-
ing in Aspergillus hyphae, may be diagnostically relevant in 
cases of invasive forms of pulmonary aspergillosis.
The treatment approach depends on the clinical criteria 
including the severity of immunosuppression, the underly-
ing disease, and the infection site. Results indicated that 
variconasole had an advantage over amphotericin B, so 
variconazole was recommended as the first-line drug [1]. 
High cost of treatment makes variconasole unavailable for 
low income countries. The administration of amphotericin 
can be associated with high nephrotixicity and undesirable 
side effects after administration, including fever, myalgia, 
nausea, vomiting, headache and bronchospasm.
The application of combined therapy regimens including 
amphotericin B in the lipid form, posaconazole, itracona-
sole, casprofungin or microfungin, has not been entirely 
standardized so far, thus additional clinical trials are re-
quired. In patients refractory to variconazole, the therapy 
of choice is amphotericin B, although resistance to one 
antifungal drug often involves resistance to others as well, 
as is the case with variconazole and itraconazole [1].
However, in this paper we presented the regression of 
symptoms after using classical antifungal drug itraconazole. 
Literature data have indicated that itraconasol induces a 
partial or complete response in 39-52% of the patients. 
The most common side effects of itraconazole include 
transient nausea and elevated liver aminotransferase lev-
els. Gastrointestinal intolerance is more common with 
oral administration of the drug. As itraconazole may oc-
casionally induce inotropic effect, it should cautiously be 
applied in patients with left ventricle dysfunction [1, 8, 9]. 
Prophylaxis with posaconazole is recommended during 
bone marrow transplantantion in patients with leukemia 
or myelodisplastic syndrome [7, 8].
Any progressive dyspnea and inspiratory stridor in im-
munodeficient patients with radiographic and CT veri-
fication of the chest lesions suggest to be considered as 
PNTB in the differential diagnosis and request appropri-
ated treatment.
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Figure 4. Bronchoscopy after therapy without fungal plaques     
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КРАТАК САДРЖАЈ
Увод Псе  у  до  мем  бра  но  зни об  лик ин  фек  ци  је Asper gil lus tra-
c he o bron chi tis је рет  ка ин  фек  ци  ја плу  ћа ко  ја се ја  вља код 
осо  ба на  ру  ше  ног имун  ског си  сте  ма.
При  каз бо  ле  сни  ка Бо  ле  сни  ца ста  ра 71 го  ди  ну ко  ја је ле  че-
на од акут  не ми  је  ло  ид  не ле  у  ке  ми  је при  мље  на је са симп-
то  ми  ма про  гре  сив  ног оте  жа  ног ди  са  ња и ин  спи  ра  тор  ним 
стри  до  ром. Ди  јаг  но  за је по  ста  вље  на на осно  ву хи  сто  ло  шког 
на  ла  за тки  ва до  би  је  ног брон  хо  ско  пи  јом. Сни  мак ком  пју-
те  ри  зо  ва  не то  мо  гра  фи  је (CT) је ука  зи  вао на за  хва  ће  ност 
тра  хе  је и лу  ме  на ле  вог глав  ног брон  ха. Ду  го  трај  но ле  че  ње 
ан  ти  ми  ко  ти  ком итра  ко  на  зо  лом у до  зи од 400 mg днев  но 
до  ве  ло је до из  ле  че  ња ове бо  ле  сни  це, што је по  твр  ђе  но и 
на кон  тр  ол  ном CT сним  ку.
За  кљу  чак Про  гре  сив  но оте  жа  но ди  са  ње и ин  спи  ра  тор  ни 
стри  дор код бо  ле  сни  ка на  ру  ше  ног здра  вља за  јед  но с ра-
ди  о  ло  шким ис  пи  ти  ва  њи  ма и CT груд  ног ко  ша ука  зу  је на то 
да тре  ба обра  ти  ти па  жњу на мо  гућ  ност по  сто  ја  ња плућ  не 
аспер  ги  ло  зе у ди  фе  рен  ци  јал  ној ди  јаг  но  зи.
Кључ  не ре  чи: аспер  ги  ло  за; акут  на ми  је  ло  ид  на ле  у  ке  ми  ја; 
тра  хе  ја; иму  но  де  фи  ци  јен  ци  ја; ан  ти  ми  ко  ти  ци
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